Questcor and its controversial flagship drug Acthar have come under fire from short sellers. The drug's many grandfathered indications and high pricing have made it an easy target as bears wait for a cheap competitor or insurer pushback. But they forgot one thing -- unless or until that happens, Questcor is a moneymaking machine.
In this video, health-care analyst David Williamson dives in to Questcor's second-quarter results in greater detail, discusses how dangerous it is to short a stock like Questcor, and talks about why this stock still may not be a good fit for Foolish investors.
Follow David on Twitter: @MotleyDavid.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Stocks Near 52-Week Highs Worth Selling
Are these three stocks sells or belles? You be the judge!
Growth in Acthar Gel Pushes Questcor's Profits Up by 84% in Q1
The expanded use of Acthar Gel sends Questcor's sales and profits soaring in the first quarter.
5 Unlikely Companies Bucking the Biotech Sell-Off
The SPDR S&P Biotech ETF is down 22.4% over the trailing month, but these five biotech stocks are all up. What's their secret?